PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products include PDS0101 and PDS01ADC. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.
| Index | Market Cap | Enterprise Value | Income | Sales | Book/sh | Cash/sh | Dividend Est. | Dividend TTM | Dividend Ex-Date | Dividend Gr. 3/5Y | Payout | Employees | IPO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 12.34M | 11.10M | -33.67M | 0.00M | -0.06 | 0.10 | - | - | - | - - | - | 21 | Oct 01, 2015 |